This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Evaluate wide market index fund performance against the SP 500 in retirement planning, emphasizing return consistency and fee impact.
28,313 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Two AI stock contenders show different paths for growth and profits. This guide explains how to read quarterly revenu...
Critics like the billionaire investor jeremy grantham call Bitcoin a mere speculative asset. This article argues why ...
Bandwidth Inc. released a mixed Q4 2025 report that sheds light on customer growth, margins, and the path to profitab...
Dell Technologies posted a billion-dollar quarter, driven by AI server orders that surged in Q4 and propelled a raise...
March 2026 brings choppy markets and rising demand for fast, reliable screeners. This piece ranks the best stock scre...
CF Industries climbs as global nitrogen supply tightens and European disruptions spill over into North American marke...
Zscaler executives argue that AI cannot substitute for 100% reliable inline traffic inspection, even as AI workloads ...
Chewy has faced a rough year, with shares falling and growth challenges ahead. Yet, a closer look under the hood show...
Palantir’s CEO has shifted away from traditional earnings calls, instead sending quarterly shareholder letters that m...
A new industry focus centers on converting existing leads. Real estate teams report faster traction by prioritizing f...
The Defense Department expanded its 1260H roster to label Alibaba and Baidu as aiding the PLA, with BYD also targeted...